Your browser doesn't support javascript.
loading
A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors.
Dasari, Arvind; Hamilton, Erika P; Falchook, Gerald S; Wang, Judy S; Li, Daneng; Sung, Max W; Chien, Caly; Nanda, Shivani; Tucci, Christopher; Hahka-Kemppinen, Marjo; Paulson, Andrew Scott.
Affiliation
  • Dasari A; MD Anderson Cancer Center, Houston, TX, USA. ADasari@mdanderson.org.
  • Hamilton EP; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA.
  • Falchook GS; Sarah Cannon Research Institute at HealthONE, Denver, CO, USA.
  • Wang JS; Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, USA.
  • Li D; City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA, USA.
  • Sung MW; Tisch Institute at The Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Chien C; HUTCHMED International Corporation, Florham Park, NJ, USA.
  • Nanda S; HUTCHMED International Corporation, Florham Park, NJ, USA.
  • Tucci C; HUTCHMED International Corporation, Florham Park, NJ, USA.
  • Hahka-Kemppinen M; HUTCHMED International Corporation, Florham Park, NJ, USA.
  • Paulson AS; Baylor Sammons Cancer Center, Dallas, TX, USA.
Invest New Drugs ; 41(3): 421-430, 2023 Jun.
Article in En | MEDLINE | ID: mdl-37074571
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neuroendocrine Tumors / Neuroectodermal Tumors, Primitive / Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: Invest New Drugs Year: 2023 Document type: Article Affiliation country: United States Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neuroendocrine Tumors / Neuroectodermal Tumors, Primitive / Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: Invest New Drugs Year: 2023 Document type: Article Affiliation country: United States Country of publication: United States